- By GF Value
The stock of Zymeworks (NYSE:ZYME, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $28.59 per share and the market cap of $1.3 billion, Zymeworks stock appears to be significantly overvalued. GF Value for Zymeworks is shown in the chart below.
Because Zymeworks is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.
Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Zymeworks has a cash-to-debt ratio of 48.86, which ranks better than 68% of the companies in Biotechnology industry. Based on this, GuruFocus ranks Zymeworks's financial strength as 7 out of 10, suggesting fair balance sheet. This is the debt and cash of Zymeworks over the past years:
Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Zymeworks has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $31.3 million and loss of $3.81 a share. Its operating margin is -627.35%, which ranks worse than 67% of the companies in Biotechnology industry. Overall, the profitability of Zymeworks is ranked 2 out of 10, which indicates poor profitability. This is the revenue and net income of Zymeworks over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Zymeworks is -31.7%, which ranks worse than 74% of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is -143.4%, which ranks in the bottom 10% of the companies in Biotechnology industry.
Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Zymeworks's return on invested capital is -139.16, and its cost of capital is 5.60. The historical ROIC vs WACC comparison of Zymeworks is shown below:
To conclude, the stock of Zymeworks (NYSE:ZYME, 30-year Financials) gives every indication of being significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the bottom 10% of the companies in Biotechnology industry. To learn more about Zymeworks stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
This article first appeared on GuruFocus.